

## Human Subjects Office FY 2013-2014 Year End Summary

### Turnaround Time (TAT)

Item	AAHRPP Mean TAT*	Q1 TAT		Q2 TAT		Q3 TAT		Q4 TAT		FY-END TAT	
		Mean	Median	Mean	Median	Mean	Median	Mean	Median	Mean	Median
<b>Full Board</b>										<b>Full Board</b>	
Full Board Protocols (to IRB Review)	<b>24.1</b>	16.7	14.0	16.9	16.5	14.5	11.0	14.6	13.0	15.5	14.0
Full Board Protocols (to IRB Approval)	<b>50.7</b>	36.2	35.5	33.2	30.5	29.2	22.0	31.4	26.0	32.5	29.0
<b>Expedited</b>										<b>Expedited</b>	
Expedited Protocols (to IRB Review)	<b>14.4</b>	6.8	6.0	6.0	4.0	4.4	2.0	3.5	1.0	5.0	3.0
Expedited Protocols (to IRB Approval)	<b>28.9</b>	7.7	6.0	6.9	5.0	5.4	2.0	4.0	2.0	5.9	3.0
<b>Exempt</b>										<b>Exempt</b>	
Exempt Protocols (to Determination)	<b>18.2</b>	2.4	0.0	4.6	3.0	3.8	2.0	2.7	1.0	3.4	2.0
<b>Amendments</b>										<b>Amendments</b>	
Amendments (to IRB Approval)	<b>N/A</b>	5.1	3.0	7.8	6.0	5.2	3.0	4.4	2.0	5.5	3.0

Turn-around-time (TAT): Is the number of calendar days between submission complete and date of review or approval.

\*Source: AAHRPP "2012 Metrics on Human Research Protection Program Performance for Academic Institutions", Updated July 18 2013.

### Throughput (T)

Item	Q1			Q2			Q3			Q4		
	Received	Completed	T	Received	Completed	T	Received	Completed	T	Received	Completed	T
Amendments	1005	970	-35	832	837	5	1010	1023	13	1073	1069	-4
Closeouts	155	163	8	107	106	-1	96	92	-4	123	127	4
Continuing Reviews	615	654	39	565	522	-43	369	418	49	393	352	-41
Continuing Reviews with Amendments	55	58	3	56	58	2	60	62	2	52	52	0
General Information (FYI)	141	123	-18	105	111	6	108	118	10	130	126	-4
Miscellaneous	85	89	4	62	62	0	69	70	1	78	81	3
Exempt Protocols	283	266	-17	329	320	-9	384	384	0	368	376	8
Expedited Protocols	197	185	-12	224	224	0	218	219	1	262	263	1
Full Board Protocols	90	78	-12	89	82	-7	83	73	-10	92	96	4
<b>TOTALS</b>	<b>2626</b>	<b>2586</b>	<b>-40</b>	<b>2369</b>	<b>2322</b>	<b>-47</b>	<b>2397</b>	<b>2459</b>	<b>62</b>	<b>2571</b>	<b>2542</b>	<b>-29</b>

Throughput (T): Is the number of completed (approved, disapproved, or withdrawn) protocols minus the number of protocols received.

**FY End total active studies: 5,824 (AAHRPP: 5,103)**